

CURRICULUM VITAE

Name	Hidekazu Suzuki	Country	Japan
Affiliation/ Present Position	Professor Division of Gastroenterology and Hepatology Department of Internal Medicine, Tokai University School of Medicine		

Education	
1983-1995	Keio University, Premedical Course, Tokyo, Japan.
1985-1989	Keio University School of Medicine, Tokyo, Japan (M.D. June, 1989)
1989-1993	Keio University, Postgraduate Course of Medicine, Tokyo, Japan
1994	Ph.D.; Thesis: "Paradoxical oxidative cell injury in hypoperfused rat liver. -Beneficial effects of prostaglandin E1-"

Training and Career (Residency and Experience)	
1993-1995	Postdoctoral Research Fellow, University of California at San Diego, La Jolla, California, U.S.A.
1995-2003	Instructor, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
2003-2011	Assistant Professor, Department of Internal Medicine, Keio University School of Medicine
2011-2015	Associate Professor, Department of Internal Medicine, Keio University School of Medicine
2015-2019	Professor, Medical Education Center, Keio University School of Medicine
2015-2019	Professor, Keio University Graduate School of Medicine
2016-present	Visiting Professor, Department of Internal Medicine, Tokyo Dental College
2017-2019	Chief, Fellowship Training Center, Keio University School of Medicine
2019-present	Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine
2019-present	Executive Director, Division of Postgraduate Clinical Training, Tokai University Hospital
2019-present	Guest Professor, School of Basic Medical Sciences, Peking University

Award and Activity
Asian Neurogastroenterology and Motility Association (ANMA) Governing Council member President of the Japanese Society for Microcirculation International Subcommittee member of American Gastroenterological Association (AGA) Rome committee member Steering Committee member of Japanese Medical Specialty Board

Research Interests
Functional Gastrointestinal Disorders (FGIDs), <i>Helicobacter pylori</i> Gastrointestinal inflammation and infection, Gastrointestinal tumor

Bibliography: representative publications from the last three years

1. Matsuzaki, J., Tsugawa, H., Kashiwazaki, Y., Mori, H., Yamamoto, Y., Kameyama, H., Masaoka, T., Kanai, T., **Suzuki, H.***. Neutrophil-activating protein polymorphism of *Helicobacter pylori* determines the host risk of dyspepsia. **Cell. Mol. Gastroenterol. Hepatol.** 8(2):295-297.e6, 2019.
2. Mori H, **Suzuki, H.***, Omata F, Masaoka T, Asaoka D, Kawakami K, Mizuno S, Kurihara N, Nagahara A, Sakaki N, Ito M, Kawamura Y, Suzuki M, Shimada Y, Sasaki H, Matsuhisa T, Torii A, Nishizawa T, Mine T, Ohkusa T, Kawai T, Tokunaga K, Takahashi S. Current status of first- and second-line *Helicobacter pylori* eradication therapy in the metropolitan area: a multicenter study with a large number of patients. **Therap Adv Gastroenterol.** 2019 Jul 4;12:1756284819858511.
3. Tsugawa, H., Mori, H., Matsuzaki, J., Sato, A., Saito, Y., Imoto, M., Suematsu, M., **Suzuki, H.*** CAPZA1 determines the risk of gastric carcinogenesis by inhibiting *Helicobacter pylori* CagA-degraded autophagy. **Autophagy** 15(2):242-258, 2019.
4. Mori H, **Suzuki, H.*** Role of acid suppression in acid-related diseases: PPI and P-CAB. **J Neurogastroenterol Motil.** 25(1):6-14, 2019.
5. **Suzuki, H.***, Matsuzaki, J. Gastric cancer: evidence boosts *H. pylori* eradication. **Nature Rev. Gastroenterol. Hepatol.** 15(8):458-460, 2018.